Compliance with guideline‐directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Coronary Artery Disease (GWTG‐CAD) program

[1]  J. De Sutter,et al.  Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology , 2015, Cardiovascular Diabetology.

[2]  Laurie Quinn,et al.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. , 2015, Circulation.

[3]  K. Kotseva,et al.  Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study , 2015, European journal of preventive cardiology.

[4]  P. Deedwania.  Gaps in guideline implementation: a cause for concern, time for action. , 2015, Journal of the American College of Cardiology.

[5]  T. Brown,et al.  Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. , 2015, Journal of the American College of Cardiology.

[6]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[7]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[8]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[9]  Deepak L. Bhatt,et al.  Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. , 2013, The American journal of medicine.

[10]  W. Shrank,et al.  The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. , 2013, The American journal of medicine.

[11]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[12]  A. Khera,et al.  Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006: Data From the National Registry of Myocardial Infarction , 2012, Circulation. Cardiovascular quality and outcomes.

[13]  Deepak L. Bhatt,et al.  Use of Renin–Angiotensin System Blockers in Acute Coronary Syndromes: Findings From Get With the Guidelines-Coronary Artery Disease Program , 2012, Circulation. Cardiovascular quality and outcomes.

[14]  Sean M. O'Brien,et al.  Comparison of Composite Measure Methodologies for Rewarding Quality of Care: An Analysis From the American Heart Association's Get With The Guidelines Program , 2011, Circulation. Cardiovascular quality and outcomes.

[15]  Deepak L. Bhatt,et al.  Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). , 2010, American heart journal.

[16]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[17]  Sean M. O'Brien,et al.  ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to develop a position statement on composite measures). , 2010, Circulation.

[18]  Susan C. Weber,et al.  STRIDE - An Integrated Standards-Based Translational Research Informatics Platform , 2009, AMIA.

[19]  D. Levy,et al.  Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study , 2009, Circulation.

[20]  P. Sham,et al.  Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. , 2009, The American journal of medicine.

[21]  B. Howard,et al.  Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.

[22]  C. Cannon,et al.  An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. , 2008, Archives of internal medicine.

[23]  L. Rydén,et al.  Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[24]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[25]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[26]  K. Narayan,et al.  Mortality Trends in Men and Women with Diabetes, 1971 to 2000 , 2007, Annals of Internal Medicine.

[27]  Simon Capewell,et al.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.

[28]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[29]  J. Spertus,et al.  Bmc Cardiovascular Disorders the Impact of Diabetes on One-year Health Status Outcomes following Acute Coronary Syndromes , 2022 .

[30]  Elizabeth R DeLong,et al.  Association between hospital process performance and outcomes among patients with acute coronary syndromes. , 2006, JAMA.

[31]  Donald M Berwick,et al.  All-or-none measurement raises the bar on performance. , 2006, JAMA.

[32]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[33]  Ralph B D'Agostino,et al.  Trends in cardiovascular complications of diabetes. , 2004, JAMA.

[34]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[35]  J. Gore,et al.  Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.

[36]  K. Eagle,et al.  Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes , 2004, Circulation.

[37]  R. Gliklich,et al.  Get With the Guidelines for Cardiovascular Secondary Prevention , 2004 .

[38]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[39]  J. Tu,et al.  Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes , 2002 .

[40]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[41]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[42]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[43]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[44]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[45]  Sean M. O'Brien,et al.  ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment: a report of American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop a Position Statement on Composite Measures). , 2010, Journal of the American College of Cardiology.

[46]  J. Leahy.  Mortality Trends in Men and Women with Diabetes, 1971 to 2000 , 2008 .

[47]  Deepak L. Bhatt,et al.  Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. , 2006, Diabetes care.

[48]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .